Altis Labs: Using AI to Accelerate Cancer Drug Development
CDL Alumni Altis Labs has raised a US$25M Series A to advance AI endpoints that can predict cancer trial outcomes months earlier.
Get new articles delivered to your inbox
CDL Alumni Altis Labs has raised a US$25M Series A to advance AI endpoints that can predict cancer trial outcomes months earlier.
CDL startups will receive OpenAI credits, and higher rate limits, giving founders more capacity to build, test, and scale with OpenAI’s technology. A select group of high-performing companies will also work directly with OpenAI teams to bring AI products to market at scale with hands-on technical support, research previews, and opportunities to provide feedback that informs future product development.